Poirier Laurence, Siegal Deborah M, Bossé Dominick, Brehaut Jamie, Dewar Brian, Lun Ronda, Shamy Michel Christopher Frank, Dowlatshahi Dar
Department of Medicine, University of Ottawa and The Ottawa Hospital Research Institute, Ottawa, Canada.
Clinical Epidemiology Program, Ottawa Hospital Research Institute, Canada.
Neurol Clin Pract. 2025 Jun;15(3):e200477. doi: 10.1212/CPJ.0000000000200477. Epub 2025 Apr 29.
The diagnostic workup for patients with cryptogenic stroke includes investigating for occult cancer, which is known to increase the risk of stroke. Current guidelines do not provide specific recommendations regarding the optimal approach for occult cancer screening after cryptogenic stroke. We surveyed Canadian stroke and thrombosis physicians to determine current workup preferences for detecting occult cancer after cryptogenic stroke.
We designed and distributed an anonymous online survey targeting physicians who manage patients with cryptogenic stroke through professional memberships of the Canadian Stroke Consortium and Thrombosis Canada. Using 4 clinical scenarios representative of patients with cryptogenic stroke with different ages (younger or older than 50 years) and from both sexes, we asked respondents which tests they routinely recommend when investigating for occult cancer among a list of laboratory investigations, imaging, and procedures. Results were analyzed using descriptive statistics.
We received 138 responses to 5 survey questions. The most commonly recommended investigations were complete blood count (79%), creatinine (63%), and coagulation tests (56%), and the most frequently recommended imaging test was CT of the abdomen and pelvis (39%). A minority of respondents indicated they would order guideline-directed age-appropriate cancer screening. Approximately half of surveyed specialists deferred the workup of cancer to a primary care physician, and 12% did not suggest any cancer workup at all.
This survey of stroke and thrombosis experts found heterogeneity in testing for cancer screening in patients with cryptogenic stroke, with the majority either not screening at all or deferring tests to primary care providers. Our survey highlights the need for better evidence and evidence-based recommendations to guide the approach to cancer screening in this population.
隐源性卒中患者的诊断检查包括对隐匿性癌症的排查,已知隐匿性癌症会增加卒中风险。目前的指南并未就隐源性卒中后隐匿性癌症筛查的最佳方法提供具体建议。我们对加拿大的卒中与血栓形成领域医生进行了调查,以确定隐源性卒中后检测隐匿性癌症的当前检查偏好。
我们设计并分发了一份匿名在线调查问卷,目标对象是通过加拿大卒中联盟和加拿大血栓形成协会的专业会员身份来管理隐源性卒中患者的医生。我们使用4个代表不同年龄(50岁以下或以上)和性别的隐源性卒中患者的临床病例,询问受访者在一系列实验室检查、影像学检查和操作中,他们在排查隐匿性癌症时常规推荐哪些检查。结果采用描述性统计方法进行分析。
我们收到了对5个调查问题的138份回复。最常被推荐的检查是全血细胞计数(79%)、肌酐(63%)和凝血检查(56%),最常被推荐的影像学检查是腹部和骨盆CT(39%)。少数受访者表示他们会安排符合指南要求的适龄癌症筛查。大约一半的受访专家将癌症检查推迟给初级保健医生,12%的专家根本不建议进行任何癌症检查。
这项对卒中和血栓形成专家的调查发现,隐源性卒中患者癌症筛查检查存在异质性,大多数专家要么根本不进行筛查,要么将检查推迟给初级保健提供者。我们的调查强调需要更好的证据和基于证据的建议来指导该人群的癌症筛查方法。